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Abstract
Magnetic resonance spectroscopy (MRS) studies have previously described metabolite changes associated with aging of the
healthy brain and provided insights into normal brain aging that can assist us in differentiating age-related changes from
those associated with neurological disease. The present study investigates whether age-related changes in metabolite
concentrations occur in the healthy cervical spinal cord. 25 healthy volunteers, aged 23–65 years, underwent conventional
imaging and single-voxel MRS of the upper cervical cord using an optimised point resolved spectroscopy sequence on a 3T
Achieva system. Metabolite concentrations normalised to unsuppressed water were quantified using LCModel and
associations between age and spinal cord metabolite concentrations were examined using multiple regressions. A linear
decline in total N-Acetyl-aspartate concentration (0.049 mmol/L lower per additional year of age, p = 0.010) and Glutamate-
Glutamine concentration (0.054 mmol/L lower per additional year of age, p = 0.002) was seen within our sample age range,
starting in the early twenties. The findings suggest that neuroaxonal loss and/or metabolic neuronal dysfunction, and
decline in glutamate-glutamine neurotransmitter pool progress with aging.
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Introduction
Human senescence is associated with deterioration in physical
performance which, in part, can be attributed to age-related
neurodegeneration of the spinal cord. Decline in motor agility and
gait are ubiquitous features of aging which can begin from the
fourth decade of life; typically, walking becomes slower, with
shortening of stride length and a tendency to stoop [1,2]. Sensory
perception across all the sensory modalities can become impaired
[3–6], with an increased incidence of bowel, bladder and erectile
dysfunction [7–10]. Studies of humans and rodents show that
advancing age is associated with aberrations of spinal myelin,
proliferation of astrocytes and reduced axonal number and
diameter within spinal sensory and motor tracts [11–13].
Quantitative morphometric studies in humans show that the
decrease in dorsal root fibres begins in the third decade of life [14],
whilst quantitative MRI has shown that diffusion anisotropy in the
upper cervical cord declines with normal aging, with loss of fibre
coherence beginning from the age of ten [15].
Conventional MRI of the spinal cord lacks the necessary
sensitivity to detect these microstructural changes. T2 hyperinten-
sities which are commonly seen in the aging brain are only rarely
seen in the spinal cord [15–17] and age-related volume loss
appears to be less marked in the spinal cord than in the brain;
although some studies have reported a negative correlation
between cord cross sectional area (CSA) and age [18,19], others
have found no change in CSA in the elderly [15,20,21]. The
development of new quantitative MRI techniques, which are more
sensitive to change in underlying tissue microstructure and
metabolism, may be much more suited to studying aging of the
spinal cord in vivo [22].
1H magnetic resonance spectroscopy (MRS), which allows the
quantification of metabolites in human tissue, has been widely
used to study healthy aging of the brain in humans [23–27] and
animals [28]. Over the past decade, developments in imaging
acquisition and post-processing, together with the availability of
high field scanners, have made it possible to use MRS to study the
spinal cord in-vivo [29,30]. Reductions in spinal cord total N-
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acetylaspartate (tNAA) concentrations are thought to reflect
neuroaxonal injury and/or mitochondrial dysfunction in patients
with multiple sclerosis, cervical spondylitic myelopathy and
amyotrophic lateral sclerosis, [31–33] while increases in spinal
cord myo-inositol/total creatine (Ins/tCr) ratios in multiple
sclerosis and following brachial plexus re-implantation [34,35]
are likely to represent a reactive gliosis. Because metabolite
concentrations reflect specific pathological processes, they could
potentially become useful imaging biomarkers of the future. Serial
MRS investigations in patients with neurodegenerative diseases
may therefore be a useful way of monitoring progression and
response to treatments. However, periodic imaging is potentially
vulnerable to temporal changes in spinal cord metabolites that are
associated with normal healthy aging, rather than disease
progression and it is, therefore, important to understand how
spinal metabolites change with age to improve interpretation of
interval changes.
To date no studies of the spinal cord have addressed metabolic
changes associated with normal aging. In this study, which was
carried out in healthy volunteers, we therefore aimed to (i)
investigate whether age was associated with changes in concen-
trations of commonly quantified metabolites and (ii) explore the
effect of gender on metabolite concentrations.
Materials and Methods
Study participants
All subjects provided written, informed consent prior to taking
part in the research, which was approved by the NRES
Committee London Bloomsbury (Formally London REC 2 Ethics
Committee).
Healthy volunteers were prospectively recruited from amongst
university staff and respondents to adverts within the university
and neurology outpatient clinic. A minimum of two subjects per
decade of life (between the ages of 20–65) were recruited in order
to achieve a good spread of ages. The age of subjects, from
youngest to oldest were; 23, 24, 25, 28, 30, 30, 31, 31, 33, 33, 36,
40, 43, 44, 46, 48, 52, 54, 55, 56, 65 and 65 years old. Participants
found to have severe spondylitic changes [16], compression of the
cord or an intrinsic cord lesion were excluded from the study.
MRI Protocol
All scans were performed using a 3T Achieva system (Philips
Medical Systems, Best, Netherlands), with the manufacturer’s 16-
channel neurovascular coil. An MR compatible cervical collar was
worn by all volunteers as this has recently been shown to
considerably reduce motion artefacts during scanning [36]. All
subjects initially underwent conventional structural imaging of the
upper cervical cord with: (a) Spin-echo T2-weighted sequence,
with TR=4000 ms; TE=100 ms; echo train length = 24 echoes;
FOV=1606250 mm2; voxel size = 0.660.663.0 mm3;number of
excitations (NEX)= 2; 13 contiguous coronal slices, and (b) Dual-
echo PD/T2-weighted sequence with TR=4000 ms; TE=15/
80 ms; FOV=2566160 mm2; voxel size = 1.061.063.0 mm3;
NEX=2; 12 contiguous sagittal slices.
Single voxel MRS data was then acquired using a recently
optimised protocol [37]. Cuboid volumes of interest (VOI) with
dimensions of approximately 5.467.76655 mm3 (2.3 ml) were
prescribed and centred on the C2/3 intervertebral disc (Figure 1)
using the previously acquired coronal and sagittal T2-weighted
and PD/T2-weighted reference scans. The dimensions of the VOI
were adjusted in the anterior-posterior (AP) dimension dependent
on the size of each subjects spinal cord (mean VOI 2.02 ml;
SD60.22 ml). MRS data was acquired using a point resolved
spectroscopy (PRESS) localisation sequence, with triggered
iterative shimming, multiply optimized insensitive suppression
train (MOIST) water suppression (available on Philips scanners)
[38–40], 4 outer volume suppression (OVS) slabs (broadband
saturation pulses approximately 5 ms duration and 6000 Hz
bandwidth, applied twice, sequentially) in the AP and rostrocaudal
directions and cardiac gating (TR=3RR<3000 ms) using a
peripheral pulse unit (350 ms delay from R-wave peak),
TE=30 ms, number of averages = 376. Details of the asymmetric
excitation RF pulse and the high-bandwidth refocusing pulse can
be found in Table S1. In addition, details of the gradient duration
and strength that apply to the default MRS voxel dimension are
shown in Table S2.
Post processing
Metabolite concentrations were quantified using the user-
independent LCModel (version 6.3) package [41] and a set of
basis spectra simulated using GAMMA [42]. The basis set
comprised seventeen metabolites including the macromolecules,
specifically, N-acetyl-aspartate (NAA), N-acetylaspartyl glutamate
(NAAG), gamma-Aminobutyric acid (GABA), Myo-inositol (Ins),
creatine (Cr), phosphocreatine (PCr), choline (Cho), phosphocho-
line (PCho), glutamate (Glu), glutamine (Gln), glucose, guanidi-
noacetate, lactate, scyllo-Inositol, taurine, alanine and aspartate.
Quantification of metabolites was performed by using the
unsuppressed water signal obtained from the same voxel [43].
NAA+NAAG (hereafter, tNAA), choline+phosphocholine (hereaf-
ter, tCho), creatine+phosphocreatine (hereafter, tCr), Ins and
Glu+Gln (hereafter, Glx) concentrations formed the focus of our
analysis. The signal-to-noise ratio (SNR) and full width of half
maximum (FWHM) of the tNAA peak provided by LCModel were
used to assess spectral quality and Crame´r-Rao Lower Bounds
(CRLB) values for each metabolite were used to assess the
reliability of the spectral fit [37]. Poor quality spectra were
excluded from the analysis. Criteria for exclusion were poor water
suppression or FWHM.0.13 with SNR,3.
Statistical analysis
All statistical analyses were performed using IBM SPSS
statistical package version 22.0 (IBM Corporation, Armonk, NY,
USA). Associations between metabolites and age were examined
using linear regression of the metabolite as response variable on
age, with gender, linewidth (FWHM) and voxel volume covariates;
a quadratic term in age was also entered to examine evidence of
non-linearity and removed if p.0.1. Gender differences reported
from these models are adjusted for age, linewidth (FWHM) and
voxel volume. P values of ,0.05 were taken to be statistically
significant.
Results
Twenty-five healthy participants were prospectively recruited
and scanned. Three participants were excluded from the analysis
due to poor spectral quality. Therefore, twenty-two healthy
participants (15 females) with a mean age of 40.5 years, standard
deviation (SD) 13.1, range 23–65 were included in the final
analysis.
Figure 2 shows typical examples of post-processed spectra
included in the final analysis. The FWHM and SNR estimated
by LCModel (reported as mean 6 SD) were 0.1160.02 ppm and
5.0561.75 respectively. Crame´r-Rao lower bounds (CRLBs)
indicated a reliable fit for tNAA, tCho, and tCr. A reliable fit
was achieved for Glx in 19 out of 22 spectra and for Ins in 20 out
Age and Metabolite Concentrations in the Spinal Cord
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of 22 spectra [44]. Mean CRLBs for each metabolites were; tNAA
(7%), tCr (11%), tCho (10%), Ins (11%) and Glx (17%).
There was no statistical evidence of a non-linear relationship
between metabolite concentrations and age. Older age predicted
lower spinal tNAA concentration (0.049 mmol/L lower per
additional year of age, p = 0.010) and lower Glx concentration
(0.054 mmol/L lower per additional year of age, p= 0.002)
(Table 1). Age was not significantly associated with the other
metabolites (Figure 3).
Glx concentration was significantly higher in men, mean (SD)
7.27 (0.97) mmol/L, than females, mean (SD) 5.73 (1.05) mmol/L
(p = 0.010, adjusting for age, FWHM and voxel volume), but no
gender differences were seen with other metabolites (Table 2).
Discussion
We used a single voxel MRS protocol optimised for improved
SNR to permit quantification of Glx from the spinal cord [37]. A
higher SNR was achieved by employing a longer voxel and
increased signal averaging compared to earlier MRS protocols
[29,30,45,46]. Although longer voxel lengths can be associated
with worsening of B0 convergence [29], our other spectral quality
indicators (FWHM and CRLB), after elimination of poor spectra,
were comparable to those published by other groups [30,46].
We aimed to evaluate whether age is associated with changes in
metabolite concentrations of the upper cervical cord, as is seen in
the brain. Using a recently optimised MRS protocol [37], we
quantified metabolite concentrations in the cervical cords of
healthy subjects aged between 23 and 65. We found that older age
was strongly associated with lower concentrations of tNAA and
Glx and that there were significantly lower Glx concentrations in
female subjects compared to males.
NAA is a non-essential amino acid which is synthesised by
neuronal mitochondria and found exclusively in neurones and
their processes [47–50]. In the spinal cord, axonal numbers closely
correlate with NAA levels quantified by immunoassay [51], and
NAA levels decrease in the presence of inhibitors of complexes I,
III, IV and V of the mitochondrial respiratory chain [52].
Therefore, in MRS studies, concentrations of tNAA are commonly
interpreted as reflecting neuroaxonal integrity and/or mitochon-
drial energy production [50]. In the current study, we observed a
linear decrease in tNAA concentrations in the upper cervical cord
with aging, and therefore hypothesise that the tNAA decline
reflects age-related neuroaxonal loss and mitochondrial dysfunc-
tion. In fact, mitochondrial DNA (MtDNA) deletions and point
Figure 1. Planning of spectroscopy scans. Coronal (a) and sagittal (b) T2-weighted images of the upper cervical cord in a healthy subject
showing voxel placement The NAA voxel (orange) is centred on the C2/3 intervertabral disc, avoiding surrounding CSF. The white voxel illustrates the
chemical shift displacement of water. Keeping both the orange voxel (on resonance, 2.02 ppm) and white voxel (4.7 ppm) within the cord, ensures
that metabolites between 2.02 and 4.7 ppm (tNAA, tCr, tCho, Glx, Ins) also arise from within the spinal cord and chemical shift displacement of each
metabolite need not be an issue. Positioning of the rostrocaudal OVS slabs is shown in periphery of images a+b and positioning of the anterior-
posterior OVS slabs is shown in c.
doi:10.1371/journal.pone.0105774.g001
Figure 2. Representative spectra obtained using LCModel from 3 study participants.
doi:10.1371/journal.pone.0105774.g002
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mutations accumulate during normal CNS aging [53,54] and,
together with increased production of reactive oxygen species [55–
57], are thought to be responsible for age-related neuroaxonal
degeneration. As our sample age range starts at 23 years, we have
not been able to ascertain whether age-related changes in the
spinal cord occur before the early twenties. Similarly, it is possible
that subjects older than 65 could show accelerated decline of
tNAA. However, within our sample age range of 23265, we did
not find a quadratic association between age and the concentra-
tions of tNAA and Glx. Future longitudinal studies will study the
decline trajectory of tNAA within individuals by following them up
for a decade or longer.
Interestingly, in healthy brain aging, reductions in tNAA have
been widely reported in grey matter regions [23,58–60], but rarely
seen in the white matter [23,58,61,62] which may, in part, be
explained by a slower rate of aging-related white matter volume
loss in the brain when compared with grey matter [63]. In a
previous brain MRS study, a different temporal behaviour of
NAA/tCho has been observed between the white matter and grey
matter. In the cerebral white matter, the NAA/tCho ratio
increases rapidly during the first decade of life before peaking in
the second or early third decade, followed by a steady decline
starting in the latter half of the third decade of life, whilst in the
grey matter, the NAA/tCho ratio enters a steady decline from
childhood [64]. Although we have not been able to assess if the
age-related decline in tNAA in the spinal cord is also tissue
dependent in the current study, due to the difficulty in segmenting
white matter and grey matter tissues within the spinal cord, it is
Figure 3. Scatter plots of relationship between age and (A) tNAA, (B) Glx, (C) tCho, (D) Ins and (E) Cr concentrations from the upper
cervical cord. Regression lines are shown where there was a significant association (A, B). No significant association was seen between age and
tCho, Ins or Cr (C–E).
doi:10.1371/journal.pone.0105774.g003
Table 1. Associations between age (predictor) and metabolite concentrations (response variable).
Association between age and metabolite concentrations
Regression coefficient Standardised regression coefficient 95% CI for regression coefficient p-value
tNAA 20.049 20.522 20.085, 20.013 0.010
Glx 20.054 20.579 20.085, 20.022 0.002
tCho 0.001 0.026 20.014, 0.015 0.920
Ins 20.006 20.067 20.055, 0.043 0.791
Cr 20.003 20.040 20.046, 0.039 0.867
Unstandardised and standardised regression coefficients calculated from the multivariate model are reported with 95% confidence intervals and p-values. The
regression models adjusted for gender, linewidth and voxel volume.
Abbreviations: tNAA =N-acetylaspartate + N-acetylaspartylglutamate, Cr = Creatine + phosphocreatine, tCho = Choline containing compounds, Ins = Myo-inositol,
Glx = glutamate/glutamine.
doi:10.1371/journal.pone.0105774.t001
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possible that tNAA concentration declines faster in spinal grey
matter than white matter with age and this could be an area for
future research.
Glutamate (Glu), the major excitatory neurotransmitter in
mammals plays a major role in the coordination of basic
propulsive movement synergy for locomotion at the spinal level
[65] and processing and transmitting sensory information in the
spinal cord [66]. Glu, as opposed to Glx, which represents a sum
of Glu and glutamine, is difficult to measure in the spinal cord. We
found that Glx concentration was negatively associated with age.
Between 75–86% of the Glx signal is thought to come from Glu
[67], and this decline in spinal Glx could largely be explained by
neuroaxonal degeneration. As Glu is largely present in neurones at
synaptic terminals, with Glu from the extracellular compartment
and glial cells considered to be present in very low concentration
and therefore contribute very little to the spectroscopy signal
[68,69], it would be expected that Glu (and therefore Glx) will
decrease where there is neuronal loss. However, it is interesting
that the rate of decline in Glx concentration with age is more rapid
than tNAA, which might suggest that the reduction in glutamate-
glutamine neurotransmitter pool are driven by more than
neuronal loss alone.
The observed association between age and Glx in the spinal
cord is in keeping with previous MRS investigations in the brain
which have consistently shown declining concentrations of Glu
with older age in multiple brain regions including the frontal white
matter, parietal grey matter, motor cortex, anterior cingulate
cortex, hippocampus, basal ganglia and striatum [24,26,68,70,71].
An interesting observation in the current study was that of
higher concentrations of Glx in men than women. MRS studies in
the brain measuring Glx and Glu concentrations have differed on
whether gender differences exist. Higher levels have been reported
in men compared to women in the parietal grey matter and
dorsolateral prefrontal cortex [25,72], whilst other studies have
reported higher concentrations in women in the cerebellum and
striatum [73]. Kaiser et al. however found no differences in Glu
and Gln concentrations between men and women in the corona
radiata and mesial motor cortex [68]. Hormonal factors may be
responsible for some of the observed gender differences in our
study. An examination of the medial prefrontal cortex during the
follicular phase and the luteal phase of the menstrual cycle found
that Glu/tCr ratios were significantly lower during the luteal phase
compared with the follicular phase [74]. Additionally, blood Glu
levels vary during the menstrual cycle such that blood Glu levels
are inversely correlated to levels of plasma oestrogen and
progesterone [75], but interestingly in the work by Zlontik et al,
Glu levels were significantly higher in men than women at any
stage of the menstrual cycle. Although the gender differences in
spinal Glx concentrations observed in this study are in keeping
with some earlier reports from the brain, further studies, with
larger sample sizes will be needed to confirm the validity of this
finding and to investigate whether spinal Glx levels vary with
female hormone levels.
In the present study no evidence of association was seen
between tCho, tCr and Ins concentrations in the spinal cord and
age. Although changes have been reported in these metabolites in
the brain with aging and have been interpreted as reflecting
changes in glial proliferation, those changes are not thought to
occur uniformly in the brain, with regional variation commonly
reported. tCho concentrations have been reported to be higher in
the corpus callosum, parietal lobe, frontal grey matter and pons in
older people [23,27,62,76], but remain stable in the frontal,
occipital and temporal lobes and the basal ganglia in other studies
[60,77] and decline in the midbrain [23]. Similarly, tCr was seen
to increase in the parietal, frontal grey and white matter
[27,62,78], but other studies found no change in tCr with aging
[60,77]. Much fewer brain studies have assessed Ins levels with
aging; a single study found an increase in the frontal grey matter
[62], whilst another study reported that Ins/tCr ratios decreased
in the frontal grey matter, basal ganglia, and occipital grey matter
[79]. A recent meta-analysis of 18 spectroscopy studies assessing
regional metabolite changes in healthy brain aging found that
there was significant increases in parietal tCho and tCr; although
fewer studies assessing changes in Ins had been carried out, levels
were not seen to change significantly in the brain with age [27].
To the best of our knowledge, this is the first report of
associations between metabolite levels and age within the spinal
cord. We have shown a possible effect of aging on tNAA and Glx
levels, which should be taken into consideration when planning
serial MRS imaging of the spinal cord in clinical and research
settings. However, it will take further longitudinal studies to
determine the rate of change in metabolites over time in healthy
aging and whether metabolite concentrations decline at differing
rates in spinal grey matter and white matter. Due to exploratory
nature of the study, our sample size was relatively small and
absolute metabolite concentrations observed within of our cohort
should therefore be interpreted with some caution until future
work, using larger sample sizes, further characterises absolute
metabolite concentrations by age group. Future experiments
should also allow additional scanning time for the inclusion of an
experimentally measured macromolecular spectrum, as this has
been shown to improve the accuracy of spectral quantification
[80]. Studies of brain aging have previously shown that age-related
metabolite changes are not uniform and can vary between brain
Table 2. Mean (SD) water scaled metabolite concentrations derived with LCModel for all subjects and by gender.
Metabolite concentrations (mmol/L) by gender
All subjects (n =22) Male (n=7) Female (n= 15)
tNAA 5.69 (1.24) 6.05 (1.37) 5.52 (1.18)
Glx 6.21 (1.24) 7.27 (0.97) 5.73 (1.05)*
tCho 1.30 (0.35) 1.36 (0.53) 1.27 (0.25)
Ins 4.70 (1.23) 5.36 (1.83) 4.42 (0.79)
Cr 3.76 (1.11) 4.15 (1.47) 3.60 (0.90)
*Significant difference in Glx concentration between male and females (p = 0.010, after adjusting for age, linewidth and voxel volume).
Abbreviations: tNAA =N-acetylaspartate + N-acetylaspartylglutamate, Cr = Creatine + phosphocreatine, tCho = Choline containing compounds, Ins = Myo-inositol,
Glx = glutamate/glutamine.
doi:10.1371/journal.pone.0105774.t002
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regions, and it is possible that metabolite changes during aging
occur at dissimilar rates at different spinal levels which will also
require further investigation.
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